{{Rsnum
|rsid=1799989
|Gene=TYR
|Chromosome=11
|position=89177755
|Orientation=plus
|GMAF=0.1694
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=TYR
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 1.8 | 17.7 | 80.5
| HCB | 1.5 | 18.2 | 80.3
| JPT | 3.5 | 23.9 | 72.6
| YRI | 11.0 | 38.6 | 50.3
| ASW | 8.8 | 29.8 | 61.4
| CHB | 1.5 | 18.2 | 80.3
| CHD | 2.8 | 18.5 | 78.7
| GIH | 3.0 | 37.6 | 59.4
| LWK | 17.4 | 44.0 | 38.5
| MEX | 1.7 | 36.2 | 62.1
| MKK | 16.7 | 44.2 | 39.1
| TSI | 1.0 | 18.6 | 80.4
| HapMapRevision=28
}}{{PMID|18855532}} among 120 (likely Japanese) first-episode neuroleptic-naive schizophrenics treated with [[risperidone]] genotyped for 30 variants in misc. dopamine and serotonin (receptors and otherwise) two SNPs in DRD2 ([[rs1799989]] and [[rs1800497]]) and two SNPs in AKT1 ([[rs3803300]] and [[rs2494732]]) were significant predictors of treatment response to risperidone

{{ClinVar
|rsid=1799989
|Reversed=0
|FwdREF=C
|FwdALT=A
|REF=C
|ALT=A
|RSPOS=88910923
|CHROM=11
|GMAF=0.1694
|dbSNPBuildID=89
|SSR=0
|SAO=0
|VP=0x05016800000017051f100100
|GENEINFO=TYR:7299
|GENE_NAME=TYR
|GENE_ID=7299
|WGT=0
|VC=SNV
|CLNALLE=1
|CLNHGVS=NC_000011.9:g.88910923C>A
|CLNSIG=5
|Tags=PM;PMC;SLO;VLD;G5A;G5;HD;GNO;KGPhase1;KGPilot123;KGPROD;OTHERKG;PH3;LSD
|CAF=0.8306; 0.1694
|CLNACC=RCV000003986.1; RCV000085882.1
|CLNDBN=Oculocutaneous albinism type 1A; not provided
|CLNDSDB=GeneReviews:MedGen:OMIM:Orphanet:Orphanet:SNOMED_CT
|CLNDSDBID=NBK1166:C0268494:203100:352731:79431:6483008
|CLNSRC=OMIM Allelic Variant; Retina International
|CLNSRCID=606933.0013; RISN-TYR:c.-199C>A
|COMMON=1
|Disease=Oculocutaneous albinism type 1A; not provided
}}

{{PMID Auto
|PMID=17999355
|Title=A genomewide association study of skin pigmentation in a South Asian population.
|OA=1
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}